TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
0 hedge funds and large institutions have $0 invested in TRACON Pharmaceuticals, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $5 → $0 (-$5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
-$5 |
TCON Hedge Fund Activity: Q4 2024 in Review
0 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2024, worth a combined $0 — down 100% from $5 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of TCON and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Game Plan Financial Advisors, exiting entirely with an estimated $5 sold.
- 0 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2024, down from 1 in Q3 2024.
- Funds reported $0 of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2024 and 1 closed out, a net change of -1 holder.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2024 was Game Plan Financial Advisors, an estimated $5 sold.
Based on aggregated 13F filings for Q4 2024.